Lindsay A. Rosenwald MD, President, CEO, and Chairman of Fortress Biotech, Inc. (NASDAQ:FBIO), filed a Form 4 on November 19, 2026, disclosing open-market purchases of common stock across three consecutive trading days.
Key Highlights
- Three-day purchase: Rosenwald acquired a combined 136,723 shares of Fortress Biotech common stock on November 17, 18, and 19, 2026.
- November 17 transaction: 64,491 shares purchased at a weighted average price of $1.7973, with individual prices ranging from $1.685 to $1.85.
- November 18 transaction: 54,776 shares purchased at a weighted average price of $1.9029, with individual prices ranging from $1.87 to $1.97.
- November 19 transaction: 17,456 shares purchased at a weighted average price of $1.8584, with individual prices ranging from $1.81 to $1.895.
- Resulting ownership: Following all three purchases, Rosenwald directly held 4,723,564 shares of common stock, par value $0.001.
- Roles: The reporting person is identified in the filing as a Director, 10% Owner, and Officer with the title President, CEO and Chairman.
Rosenwald's Open-Market Purchases of Fortress Biotech Common Stock
According to the Form 4 filed with the SEC on November 19, 2026, Lindsay A. Rosenwald MD conducted purchases of Fortress Biotech, Inc. common stock (NASDAQ:FBIO) over three consecutive trading days. All transactions are recorded under transaction code "P," indicating open-market purchases. The filing notes that the prices reported are weighted average prices, and that the shares were acquired in multiple transactions within disclosed price ranges on each date.
On November 17, 2026, the filing reports 64,491 shares acquired at a weighted average of $1.7973, bringing Rosenwald's directly held total to 4,651,332 shares. The following day, November 18, an additional 54,776 shares were acquired at a weighted average of $1.9029, raising the directly held total to 4,706,108 shares. On November 19, 2026, the date the form was filed, a further 17,456 shares were acquired at a weighted average of $1.8584, resulting in a directly held position of 4,723,564 shares.
The filing states that Rosenwald "undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this note." No derivative securities transactions were reported. The form was signed by David Jin as Attorney-in-Fact on November 19, 2026.
What Was Disclosed
The Form 4 discloses three open-market purchases of Fortress Biotech common stock by President, CEO, and Chairman Lindsay A. Rosenwald MD between November 17 and November 19, 2026, totaling 136,723 shares acquired at weighted average prices between $1.7973 and $1.9029.




Please wait processing your request...